Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street
12. Dezember 2024 02:00 ET
|
Essential Pharma
Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street Provides significant resources to...
Essential Pharma Announces the Appointment of Dr Liz Holmes as Chief Medical Officer
16. Oktober 2024 02:00 ET
|
Essential Pharma
Essential Pharma Announces the Appointment of Dr Liz Holmes as Chief Medical Officer Newly established role at Essential Pharma further strengthens leadership team and supports global growth Dr Liz...
Essential Pharma launches campaign with International Health Partners to donate life-saving medicines to disaster-hit countries
10. Juli 2024 02:00 ET
|
Essential Pharma
Essential Pharma launches campaign with International Health Partners to donate life-saving medicines to disaster-hit countries Donations to help support over 30,000 patients in disaster-hit and...
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma
11. Juni 2024 02:00 ET
|
Essential Pharma
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma Egham, UK and Copenhagen,...
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
17. April 2024 02:00 ET
|
Essential Pharma
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe...
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
09. April 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
08. Januar 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in...
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board
21. Juni 2023 02:00 ET
|
Essential Pharma
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board Zug, Switzerland & Egham, UK – 21 June 2023 – Essential Pharma, an international specialty pharma group focused on...
Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer
24. Mai 2023 02:00 ET
|
Essential Pharma
Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer Zug, Switzerland & Egham, UK – 24 May 2023 – Essential Pharma, an international specialty pharma company...
UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need for product
15. Dezember 2022 07:06 ET
|
Essential Pharma
UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need...